PDF(Sci-hub)
Abstract：
BACKGROUND: Novel immune checkpoint-based immunotherapies may benefit specific groups of prostate cancer patients who are resistant to other treatments.
METHODS: We analyzed by immunohistochemistry the expression of B7-H3, PD-L1/B7-H1, and androgen receptor (AR) in tissue samples from 120 prostate adenocarcinoma patients treated with radical prostatectomy in Spain, and from 206 prostate adenocarcinoma patients treated with radical prostatectomy in Norway.
RESULTS: B7-H3 expression correlated positively with AR expression and was associated with biochemical recurrence in the Spanish cohort, but PD-L1 expression correlated with neither of them. Findings for B7-H3 were validated in the Norwegian cohort, where B7-H3 expression correlated positively with Gleason grade, surgical margins, seminal vesicle invasion, and CAPRA-S risk group, and was associated with clinical recurrence. High B7-H3 expression in the Norwegian cohort was also consistent with positive AR expression.
CONCLUSIONS: These results suggest distinct clinical relevance of the two immune checkpoint proteins PD-L1 and B7-H3 in prostate cancer. Our findings highlight B7-H3 as an actionable novel immune checkpoint protein in prostate cancer.
METHODS: We analyzed by immunohistochemistry the expression of B7-H3, PD-L1/B7-H1, and androgen receptor (AR) in tissue samples from 120 prostate adenocarcinoma patients treated with radical prostatectomy in Spain, and from 206 prostate adenocarcinoma patients treated with radical prostatectomy in Norway.
RESULTS: B7-H3 expression correlated positively with AR expression and was associated with biochemical recurrence in the Spanish cohort, but PD-L1 expression correlated with neither of them. Findings for B7-H3 were validated in the Norwegian cohort, where B7-H3 expression correlated positively with Gleason grade, surgical margins, seminal vesicle invasion, and CAPRA-S risk group, and was associated with clinical recurrence. High B7-H3 expression in the Norwegian cohort was also consistent with positive AR expression.
CONCLUSIONS: These results suggest distinct clinical relevance of the two immune checkpoint proteins PD-L1 and B7-H3 in prostate cancer. Our findings highlight B7-H3 as an actionable novel immune checkpoint protein in prostate cancer.
摘要：
背景：基于免疫检查点的新型免疫疗法可能会使对其他治疗有抗性的前列腺癌患者的特定群体受益。
方法：我们通过免疫组织化学分析了120例接受根治性前列腺切除术治疗的前列腺腺癌患者的组织样本中B7-H3，PD-L1/B7-H1和雄激素受体（AR）的表达在西班牙，以及挪威接受根治性前列腺切除术治疗的206例前列腺腺癌患者。
结果：西班牙队列中B7-H3表达与AR表达呈正相关，与生化复发相关，但PD-L1表达与两者均不相关。B7-H3的发现在挪威队列中得到了验证，其中B7-H3表达与格里森等级呈正相关，手术切缘,精囊侵入，和CAPRA-S风险组，并与临床复发有关。挪威队列中的高B7-H3表达也与阳性AR表达一致。
结论：这些结果表明两种免疫检查点蛋白PD-L1和B7-H3在前列腺癌中具有明显的临床相关性。我们的发现强调B7-H3是前列腺癌中一种可行的新型免疫检查点蛋白。
方法：我们通过免疫组织化学分析了120例接受根治性前列腺切除术治疗的前列腺腺癌患者的组织样本中B7-H3，PD-L1/B7-H1和雄激素受体（AR）的表达在西班牙，以及挪威接受根治性前列腺切除术治疗的206例前列腺腺癌患者。
结果：西班牙队列中B7-H3表达与AR表达呈正相关，与生化复发相关，但PD-L1表达与两者均不相关。B7-H3的发现在挪威队列中得到了验证，其中B7-H3表达与格里森等级呈正相关，手术切缘,精囊侵入，和CAPRA-S风险组，并与临床复发有关。挪威队列中的高B7-H3表达也与阳性AR表达一致。
结论：这些结果表明两种免疫检查点蛋白PD-L1和B7-H3在前列腺癌中具有明显的临床相关性。我们的发现强调B7-H3是前列腺癌中一种可行的新型免疫检查点蛋白。
